Two Sigma Advisers
CGTX icon

Two Sigma Advisers’s Cognition Therapeutics CGTX Stock Holding History

Two Sigma Advisers’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,000
Closed -$5.16K – 2361
2024
Q3 		$5.16K Buy
+11,000
New +$11.3K ﹤0.01% 2259
2022
Q3 		– Sell
-15,600
Closed -$33K – 2568
2022
Q2 		$33K Sell
15,600
-12,500
-44% -$32.3K ﹤0.01% 2513
2022
Q1 		$77K Sell
28,100
-40,800
-59% -$157K ﹤0.01% 2538
2021
Q4 		$435K Buy
+68,900
New +$672K ﹤0.01% 1981

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers's CGTX Position: Q4 2024 in Review

Two Sigma Advisers sold out of Cognition Therapeutics (CGTX) in Q4 2024, closing a stake of 11,000 shares — an estimated $5.16K sold.

Two Sigma Advisers first reported a position in CGTX in Q4 2021 and held it in 4 quarters. The position peaked at $435K in Q4 2021. 45 funds tracked by Wall St. Rank hold CGTX as of Q4 2024.

  • Two Sigma Advisers reported no remaining Cognition Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 11,000 Cognition Therapeutics shares in Q4 2024, an estimated $5.16K.
  • Two Sigma Advisers first reported a position in Cognition Therapeutics in Q4 2021 and held it in 4 quarters.
  • Two Sigma Advisers's Cognition Therapeutics position peaked at $435K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q4 2024.

Based on Two Sigma Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.